Article Collection
Special themed collection: The changing face of migraine
Editors: Messoud Ashina, Lars Edvinsson, Paolo Martelletti The Journal of Headache and Pain.
Migraine management has long relied on medication developed to treat other conditions. However, the emergence of a new class of preventative drugs is now within our grasp. Targeted prophylactic migraine treatment is becoming a reality and the neuropeptide calcitonin gene-related peptide (CGRP) plays a central role in this breakthrough.
This topical collection explores the changing face of migraine and examines where we are in meeting the long-standing unmet need for a more individualized and targeted approach.
Editorial
- The changing face of migraine
Paolo Martelletti, Messoud Ashina and Lars Edvinsson
Review articles
- Identifying and managing refractory migraine: barriers and opportunities?
Linda D’Antona & Manjit Matharu - Advances in genetics of migraine
Heidi G. Sutherland, Cassie L. Albury and Lyn R. Griffiths - Optimising migraine treatment: from drug-drug interactions to personalized medicine
Leda Marina Pomes, Martina Guglielmetti, Enrico Bertamino, Maurizio Simmaco, Marina Borro and Paolo Martelletti - The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse
Willem Sebastiaan van Hoogstraten and Antoinette MaassenVanDenBrink - How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Cindy Tiseo, Raffaele Ornello, Francesca Pistoia and Simona Sacco - A narrative review on the burden of migraine: when the burden is the impact on people’s life
Matilde Leonardi and Alberto Raggi - Therapeutic novelties in migraine: new drugs, new hope?
Thien Phu Do, Song Guo and Messoud Ashina - Identifying and managing refractory migraine: barriers and opportunities?
Linda D’Antona and Manjit Matharu
Perspective
- Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
Paolo Martelletti, Lars Edvinsson and Messoud Ashina
Funding
The APCs (article processing charges) for the articles in this thematic series ‘The changing face of migraine’ were made possible through independent educational sponsorship by Eli Lilly and Company. Eli Lilly and Company provided the funds through an educational grant which included enduring materials within the context of a symposium at the 12th European Headache Federation Congress in September 2018, chaired by Paolo Martelletti. This grant was provided to Springer Healthcare IME who organized the symposium and all of the enduring materials. Three of the articles in this thematic series were developed from content presented at the symposium. Eli Lilly and Company were not involved in the planning of the thematic series, the selection process for topics, nor in any peer review or decision-making processes.
The articles have undergone the journal’s standard peer review process overseen by the Editor-in-Chief. For articles where the Editor-in-Chief is an author, the peer review process was overseen by one of the other Editors responsible for this thematic series.
The costs for printing and distributing the thematic collection were covered within the educational grant provided by Eli Lilly and Company.